SANA Fundamental Analysis - SANA BIOTECHNOLOGY INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to SANA. SANA was compared to 558 industry peers in the Biotechnology industry. While SANA seems to be doing ok healthwise, there are quite some concerns on its profitability. SANA has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SANA has reported negative net income.

In the past year SANA has reported a negative cash flow from operations.

SANA had negative earnings in each of the past 5 years.

SANA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

SANA has a Return On Assets (-46.84%) which is comparable to the rest of the industry.

SANA has a Return On Equity (-99.81%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-46.84%
ROE	-99.81%
ROIC	N/A

ROA(3y)-45.37%

ROA(5y)-41.34%

ROE(3y)-86.33%

ROE(5y)-74.79%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SANA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, SANA has more shares outstanding

Compared to 5 years ago, SANA has more shares outstanding

There is no outstanding debt for SANA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

SANA has an Altman-Z score of -5.18. This is a bad value and indicates that SANA is not financially healthy and even has some risk of bankruptcy.

SANA has a Altman-Z score (-5.18) which is comparable to the rest of the industry.

There is no outstanding debt for SANA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-5.18

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

SANA has a Current Ratio of 3.40. This indicates that SANA is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 3.40, SANA is doing worse than 60.75% of the companies in the same industry.

A Quick Ratio of 3.40 indicates that SANA has no problem at all paying its short term obligations.

SANA has a Quick ratio of 3.40. This is comparable to the rest of the industry: SANA outperforms 40.86% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.4
Quick Ratio	3.4

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.14% over the past year.

EPS 1Y (TTM)40.14%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%57.14%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SANA will show a small growth in Earnings Per Share. The EPS will grow by 7.52% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y32.61%

EPS Next 2Y15.38%

EPS Next 3Y9.31%

EPS Next 5Y7.52%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SANA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year SANA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y15.38%

EPS Next 3Y9.31%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SANA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SANA BIOTECHNOLOGY INC

NASDAQ:SANA (6/4/2025, 10:33:57 AM)

2.33

-0.01 (-0.43%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-08 2025-05-08/amc

Earnings (Next)08-06 2025-08-06/amc

Inst Owners94.42%

Inst Owner Change-5.45%

Ins Owners8.68%

Ins Owner Change0.38%

Market Cap525.55M

Analysts84.29

Price Target9.69 (315.88%)

Short Float %20.1%

Short Ratio11.05

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)9.68%

Min EPS beat(2)9.03%

Max EPS beat(2)10.32%

EPS beat(4)4

Avg EPS beat(4)12.24%

Min EPS beat(4)1.83%

Max EPS beat(4)27.76%

EPS beat(8)5

Avg EPS beat(8)7.62%

EPS beat(12)9

Avg EPS beat(12)11.29%

EPS beat(16)12

Avg EPS beat(16)10.69%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-9.52%

EPS NQ rev (1m)15.09%

EPS NQ rev (3m)6.43%

EPS NY rev (1m)14.02%

EPS NY rev (3m)12.31%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	2.51
P/tB	56.77
EV/EBITDA	N/A

EPS(TTM)-0.88

EYN/A

EPS(NY)-0.78

Fwd EYN/A

FCF(TTM)-0.99

FCFYN/A

OCF(TTM)-0.91

OCFYN/A

SpS0

BVpS0.93

TBVpS0.04

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-46.84%
ROE	-99.81%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-45.37%

ROA(5y)-41.34%

ROE(3y)-86.33%

ROE(5y)-74.79%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	102.47%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.4
Quick Ratio	3.4
Altman-Z	-5.18

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)135.8%

Cap/Depr(5y)216.07%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)40.14%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%57.14%

EPS Next Y32.61%

EPS Next 2Y15.38%

EPS Next 3Y9.31%

EPS Next 5Y7.52%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y35.08%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year31.03%

EBIT Next 3Y4.22%

EBIT Next 5YN/A

FCF growth 1Y27.1%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y29.3%

OCF growth 3YN/A

OCF growth 5YN/A

SANA BIOTECHNOLOGY INC (SANA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens